In various rheumatological disease states, the inhibition of S100A8 or calprotectin via small molecule inhibitors or antibodies is a very attractive therapeutic strategy; early studies of such inhibitors are already showing therapeutic efficacy in both human trials and/or in mouse models, including in studies for arthritis, asthma, IBD, and multiple sclerosis (reviewed in [86]). Here, S100A8 is linked to asthma.